This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AZ&Me™ Prescription Savings Program For People With Medicare Part D Removes Out-of-Pocket Spend Requirement

Stocks in this article: AZN

AstraZeneca (NYSE:AZN) today announced that it is simplifying the enrollment process for the AZ&Me™ Prescription Savings Program for people with Medicare Part D by removing an out-of-pocket spend requirement.

As of Jan. 1, the program will no longer require that people with Medicare prescription drug coverage spend 3 percent of their annual household income on out-of-pocket costs for prescription medicines within the calendar year to qualify.

Those who meet all of the other program eligibility requirements may begin receiving their AstraZeneca medicines for free upon successfully completing the enrollment process. To be eligible for the program, a Medicare beneficiary must:

  • Be enrolled in Medicare Part D.
  • Have an annual household income at or below $35,000 for individuals or $48,000 for couples.
  • Not be enrolled in the Medicare Limited Income Subsidy.

"We regularly evaluate how we can simplify our program enrollment process and saw an opportunity to do so for people with Medicare prescription drug coverage," said Jennifer McGovern, Director, AZ&Me Prescription Savings Programs. "Removing the out-of-pocket spend requirement means that people will no longer have to gather documentation from their pharmacy before completing their enrollment, saving them time and helping them get their AstraZeneca medicines sooner."

AstraZeneca has offered prescription savings programs for 34 years and offers one of the industry’s most generous programs. The company will continue to make program enhancements that better serve patients and the advocates who help them.

"Prescription assistance programs help fill an important need for many people who have Medicare Part D coverage, but may not be able to access all of their medicines because of limited financial resources," said Nora Dowd Eisenhower, senior vice president for economic security and director of the Center for Benefits Access, National Council on Aging. "We salute AstraZeneca for its continued leadership in patient assistance and will use this opportunity to remind Medicare beneficiaries, caregivers and advocates that these kinds of programs are a helpful resource for many who don’t qualify for extra help through the Medicare Limited Income Subsidy."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs